- Home
- BDRX vs MTNB Comparison
BDRX vs MTNB Comparison
Compare BDRX & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- MTNB
- Stock Information
- Founded
- BDRX 2000
- MTNB 2013
- Country
- BDRX United Kingdom
- MTNB United States
- Employees
- BDRX N/A
- MTNB N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- MTNB Biotechnology: Pharmaceutical Preparations
- Sector
- BDRX Health Care
- MTNB Health Care
- Exchange
- BDRX Nasdaq
- MTNB Nasdaq
- Market Cap
- BDRX 3.7M
- MTNB 3.1M
- IPO Year
- BDRX N/A
- MTNB N/A
- Fundamental
- Price
- BDRX $1.55
- MTNB $0.67
- Analyst Decision
- BDRX
- MTNB Hold
- Analyst Count
- BDRX 0
- MTNB 1
- Target Price
- BDRX N/A
- MTNB N/A
- AVG Volume (30 Days)
- BDRX 1.2M
- MTNB 32.8K
- Earning Date
- BDRX 05-02-2025
- MTNB 04-15-2025
- Dividend Yield
- BDRX N/A
- MTNB N/A
- EPS Growth
- BDRX N/A
- MTNB N/A
- EPS
- BDRX N/A
- MTNB N/A
- Revenue
- BDRX N/A
- MTNB N/A
- Revenue This Year
- BDRX N/A
- MTNB N/A
- Revenue Next Year
- BDRX N/A
- MTNB N/A
- P/E Ratio
- BDRX N/A
- MTNB N/A
- Revenue Growth
- BDRX N/A
- MTNB N/A
- 52 Week Low
- BDRX $1.14
- MTNB $0.48
- 52 Week High
- BDRX $74.00
- MTNB $9.70
- Technical
- Relative Strength Index (RSI)
- BDRX 43.94
- MTNB 64.44
- Support Level
- BDRX $1.24
- MTNB $0.54
- Resistance Level
- BDRX $1.52
- MTNB $0.60
- Average True Range (ATR)
- BDRX 0.20
- MTNB 0.05
- MACD
- BDRX 0.07
- MTNB 0.01
- Stochastic Oscillator
- BDRX 49.21
- MTNB 100.00
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.